Objectives: We investigated the significance of microbial translocation measured on average 3 years after HIV seroconversion in driving disease progression in HIV untreated patients with high ACD4+ cell count. Design: We included ICONA patients with documented last HIV-negative and first HIV-positive test, at least one plasma sample stored while antiretroviral therapy (ART)-naive and ACD4+ cell count greater than 200 cells/μl. Methods: Microbial translocation [lipopolysaccharide (LPS), sCD14 and EndoCAb] and immune activation (IL-6 and TNF-α) were measured. Correlation between immune activation, microbial translocation, ACD4+ and plasma HIV-RNA was evaluated by linear regression and nonparametric Spearmans rho. The independent predictive value of these markers on time to progression to the combined endpoint of AIDS, death, ACD4+ cell count less than 200 cells/μl or start of antiretroviral therapy (ART) was assessed using survival analysis. Results: We analysed 1488 biomarker measures from 379 patients. A median of 3.1 years after the estimated seroconversion date [interquartile range (IQR) 1.6-5.4], median (IQR) markers values were LPS, 110pg/ml (IQR 75-215), sCD14, 3.3μg/ml (2.2-4.8), IL-6, 1.1pg/ml (0.6-1.9) and TNF-α, 2.4pg/ml (1.8-3.4). Two hundred and sixty progression events were recorded over a median of 1.6 years from the first sample (2% AIDS, 84% ART initiation, 12% ACD4+ cell count less than 200 cells/μl and 2% death). LPS was the only biomarker associated with this primary composite outcome independently of age, HIV-RNA and ACD4+ (relative hazard=1.40 per loge higher, 95% confidence interval 1.18-1.66, P<0.001). Conclusion: Circulating LPS in the first years of chronic HIV infection is a strong predictor of disease progression independent of ACD4+ cell count and HIV viraemia and may be considered a candidate biomarker for HIV monitoring and evaluation in clinical trials

Marchetti, G., Cozzi Lepri, A., Merlini, E., Bellistrì, G., Castagna, A., Galli, M., et al. (2011). Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS, 25(11), 1385-1394 [10.1097/QAD.0b013e3283471d10].

Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count

GORI, ANDREA
2011

Abstract

Objectives: We investigated the significance of microbial translocation measured on average 3 years after HIV seroconversion in driving disease progression in HIV untreated patients with high ACD4+ cell count. Design: We included ICONA patients with documented last HIV-negative and first HIV-positive test, at least one plasma sample stored while antiretroviral therapy (ART)-naive and ACD4+ cell count greater than 200 cells/μl. Methods: Microbial translocation [lipopolysaccharide (LPS), sCD14 and EndoCAb] and immune activation (IL-6 and TNF-α) were measured. Correlation between immune activation, microbial translocation, ACD4+ and plasma HIV-RNA was evaluated by linear regression and nonparametric Spearmans rho. The independent predictive value of these markers on time to progression to the combined endpoint of AIDS, death, ACD4+ cell count less than 200 cells/μl or start of antiretroviral therapy (ART) was assessed using survival analysis. Results: We analysed 1488 biomarker measures from 379 patients. A median of 3.1 years after the estimated seroconversion date [interquartile range (IQR) 1.6-5.4], median (IQR) markers values were LPS, 110pg/ml (IQR 75-215), sCD14, 3.3μg/ml (2.2-4.8), IL-6, 1.1pg/ml (0.6-1.9) and TNF-α, 2.4pg/ml (1.8-3.4). Two hundred and sixty progression events were recorded over a median of 1.6 years from the first sample (2% AIDS, 84% ART initiation, 12% ACD4+ cell count less than 200 cells/μl and 2% death). LPS was the only biomarker associated with this primary composite outcome independently of age, HIV-RNA and ACD4+ (relative hazard=1.40 per loge higher, 95% confidence interval 1.18-1.66, P<0.001). Conclusion: Circulating LPS in the first years of chronic HIV infection is a strong predictor of disease progression independent of ACD4+ cell count and HIV viraemia and may be considered a candidate biomarker for HIV monitoring and evaluation in clinical trials
Articolo in rivista - Articolo scientifico
Scientifica
Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Confidence Intervals; Disease Progression; Female; HIV Seropositivity; HIV-1; Humans; Male; Microbial Viability; Middle Aged; Viral Load; Young Adult
English
Marchetti, G., Cozzi Lepri, A., Merlini, E., Bellistrì, G., Castagna, A., Galli, M., et al. (2011). Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS, 25(11), 1385-1394 [10.1097/QAD.0b013e3283471d10].
Marchetti, G; Cozzi Lepri, A; Merlini, E; Bellistrì, G; Castagna, A; Galli, M; Verucchi, G; Antinori, A; Costantini, A; Giacometti, A; di Caro, A; D'arminio Monforte, A; Gori, A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/63469
Citazioni
  • Scopus 153
  • ???jsp.display-item.citation.isi??? 144
Social impact